Parabilis Medicines (NASDAQ:PBLS) Upgraded by Zacks Research to Hold Rating

Zacks Research upgraded shares of Parabilis Medicines (NASDAQ:PBLS) to a hold rating in a report published on Tuesday morning,Zacks.com reports.

A number of other brokerages have also recently weighed in on PBLS. Leerink Partners started coverage on shares of Parabilis Medicines in a report on Monday. They issued an “outperform” rating and a $40.00 price objective for the company. Wall Street Zen upgraded Parabilis Medicines to a “hold” rating in a report on Saturday, June 20th. Evercore started coverage on Parabilis Medicines in a research report on Monday. They issued an “outperform” rating on the stock. Guggenheim initiated coverage on Parabilis Medicines in a research report on Monday. They issued a “buy” rating and a $40.00 price target on the stock. Finally, Lifesci Capital upgraded Parabilis Medicines to a “strong-buy” rating in a research note on Monday. One analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating and one has issued a Hold rating to the company’s stock. According to MarketBeat, Parabilis Medicines has a consensus rating of “Buy” and an average target price of $41.67.

Parabilis Medicines Price Performance

Shares of PBLS opened at $30.83 on Tuesday. Parabilis Medicines has a 1-year low of $24.51 and a 1-year high of $34.47.

Insider Buying and Selling at Parabilis Medicines

In other news, Director Alan Sebulsky bought 9,065 shares of the stock in a transaction that occurred on Monday, June 15th. The stock was purchased at an average price of $26.49 per share, for a total transaction of $240,131.85. Following the completion of the purchase, the director owned 30,000 shares in the company, valued at approximately $794,700. This trade represents a 43.30% increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, major shareholder Guy Levy purchased 500,000 shares of the business’s stock in a transaction on Thursday, June 11th. The stock was acquired at an average price of $20.00 per share, for a total transaction of $10,000,000.00. Following the completion of the purchase, the insider owned 1,027,000 shares of the company’s stock, valued at $20,540,000. This represents a 94.88% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Over the last ninety days, insiders have bought 530,000 shares of company stock valued at $10,723,528.

Key Headlines Impacting Parabilis Medicines

Here are the key news stories impacting Parabilis Medicines this week:

• Positive Sentiment: Lifesci Capital upgraded Parabilis Medicines to Strong-Buy and reiterated favorable earnings expectations across 2026 and 2027, signaling confidence in the company’s outlook. Tickerreport.com
• Positive Sentiment: Guggenheim initiated coverage on Parabilis Medicines with a Buy rating and a $40 price target, implying meaningful upside from current trading levels. Tickerreport.com
• Positive Sentiment: Bank of America and Leerink Partners also began coverage, adding to the growing analyst attention around PBLS and reinforcing investor interest. American Banking News
• Neutral Sentiment: Lifesci Capital’s detailed EPS estimates point to continued losses in several upcoming quarters and full years, which may temper enthusiasm despite the bullish rating. MarketBeat